Shilpa Medicare Ltd. (BSE: 530549) is a Raichur, Karnataka-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹19,312 Cr, it ranks #378 by market cap among the 6,197 Indian listed companies on FinBizNet, and #17 of 86 in Medicinal Chemicals and Botanical Products. At ₹983.20 (as of 16 Nov 2026), the share price is 10.2% below its 52-week high of ₹1,095.00 and 268.2% above its 52-week low of ₹267.00. The share price is up 169.0% over one year and up 22.9% over three months.
| Current Price | ₹983.20 |
|---|---|
| Market Cap | ₹19,312 Cr |
| BSE Code | 530549 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 80.4 |
| Return on Equity | 9.82% |
| Return on Assets | 4.68% |
| 52-Week Range | ₹267.00 – ₹1,095.00 |
| 1-Year Price Change | +169.0% |
| 3-Month Price Change | +22.9% |
| Beta (1Y) | 0.33 |
| Dividend Yield | 0.06% |
| Headquarters | Raichur, Karnataka |
| Website | www.vbshilpa.com |
| Revenue | ₹529 Cr |
|---|---|
| Net Profit | ₹79 Cr |
| Net Margin | 15.0% |
| EPS (Basic) | ₹4.05 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Shilpa Medicare Ltd. reported revenue of ₹529 Cr in Q2 FY27, up 43.0% from ₹370 Cr in Q2 FY26 and up 13.6% from ₹466 Cr in Q1 FY27. It posted a net profit of ₹79 Cr for the quarter, against a net profit of ₹44 Cr in Q2 FY26 (up 79.7%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹321 Cr (Q1 FY26) to ₹529 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹529 Cr | ₹79 Cr | 15.0% |
| Q1 FY27 | ₹466 Cr | ₹101 Cr | 21.7% |
| Q4 FY26 | ₹437 Cr | ₹108 Cr | 24.7% |
| Q3 FY26 | ₹410 Cr | ₹45 Cr | 10.9% |
| Q2 FY26 | ₹370 Cr | ₹44 Cr | 11.9% |
| Q1 FY26 | ₹321 Cr | ₹47 Cr | 14.6% |
| Q4 FY25 | ₹331 Cr | ₹15 Cr | 4.4% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 40.13% of Shilpa Medicare Ltd.'s shares as of Sept 2026, against 44.23% in Sept 2025 (−4.10 percentage points). Delivery averaged 42.7% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Shilpa Medicare Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, biosimilars, and contract development and manufacturing organisation in India, the United States, Europe, and internationally. The company offers various oncology and non-oncology APIs, such as anastrozole, acebrophylline, ambroxol hydrochloride, axitinib, azacitidine, abiraterone acetate, bendamustine HCL monohydrate, bicalutamide, bortezomib, busulphan, cabazitaxel amorphous, capecitabine, clofarabine, cyclophosphamide, dasatinib, decitabine, dimethyl fumarate, erlotinib HCL, enzalutamide, fingolimod hydrochloride, gemcitabine HCl, ibrutinib, imatinib mesylate, irinotecan HCl trihydrate, lenalidomide, lenvatinib mesylate, letrozole, and melphalan HCL. It also provides nifedipine, oxaliplatin, pazopanib, pemetrexed disodium hemipentahydrate, pemetrexed dipotassium nonahydrate, pirfenidone, pomalidomide, sodium cholesteryl sulfate, sora
1. Pharmaceutical Product and Wind Power Generation-This segment manufactures and sells bulk drugs and intermediates. 2. Energy-0 3. Segment Adjustment-This segment is involved in the generation of wind power. 4. Bulk Drug & API-This segment is engaged in the manufacture and sale of bulk drugs and intermediates in India. It offers oncology products, active pharmaceutical ingredients, fine chemicals, herbal products, and specialty chemical products.
1. Pharmaceuticals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,56,425 Cr | 39.5 | 14.72% | ₹16,199 Cr | +11.2% |
| Laurus Labs Ltd | ₹1,31,242 Cr | 145.6 | 17.74% | ₹2,206 Cr | +146.8% |
| Zydus Lifesciences Ltd | ₹1,19,651 Cr | 24.1 | 18.32% | ₹7,910 Cr | +26.0% |
| Dr.Reddys Lab | ₹1,15,464 Cr | 26.9 | 11.52% | ₹8,698 Cr | +14.5% |
| Cipla Limited | ₹1,14,712 Cr | 29.3 | 11.74% | ₹7,404 Cr | -7.6% |
| Mankind Pharma | ₹1,09,870 Cr | 57 | 12.45% | ₹4,338 Cr | +16.7% |
| Aurobindo Pharma Ltd. | ₹1,05,150 Cr | 30 | 9.93% | ₹10,263 Cr | +59.8% |
| Lupin Ltd | ₹92,087 Cr | 17.3 | 26.91% | ₹7,827 Cr | +0.4% |
| Shilpa Medicare Ltd. | ₹19,312 Cr | 80.4 | 9.82% | ₹529 Cr | +169.0% |
Listed by market capitalisation. Ratios are shown for context only.
Shilpa Medicare Ltd. is trading at ₹983.20, with a market capitalisation of ₹19,312 Cr.
Shilpa Medicare Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Shilpa Medicare Ltd. has a P/E of 80.4 and a return on equity of 9.82%.
Shilpa Medicare Ltd. is listed on the BSE under the scrip code 530549.
Shilpa Medicare Ltd.'s share price is up 169.0% over one year and up 22.9% over three months. Its 52-week range is ₹267.00 to ₹1,095.00.
In Q2 FY27, Shilpa Medicare Ltd. reported revenue of ₹529 Cr and net profit of ₹79 Cr, with basic EPS of ₹4.05 (consolidated, parsed from the company's exchange filing).
Shilpa Medicare Ltd. reported revenue of ₹529 Cr in Q2 FY27, up 43.0% from ₹370 Cr in Q2 FY26 and up 13.6% from ₹466 Cr in Q1 FY27.
Promoters held 40.13% of Shilpa Medicare Ltd.'s shares as of Sept 2026, against 44.23% in Sept 2025 (−4.10 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.